ArticleMedicine2026
Association between serum zinc levels and new-onset hypertension: A 5-year retrospective cohort study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The relationship between zinc deficiency and incident hypertension remains poorly characterized in humans. We examined the association between zinc deficiency and new-onset hypertension and related complications. This retrospective cohort study utilized the TriNetX Research Network to analyze adult patients with serum zinc measurements between January 2010 and December 2023. The zinc-deficient group had concentrations below 0.7 µg/mL, while controls ranged from 0.70 to 1.20 µg/mL. Following propensity score matching, 47,843 pairs were analyzed over 5 years. The primary outcome was new-onset primary hypertension. Secondary outcomes included secondary hypertension, hypertension-related cardiac and renal complications, and hypertensive crisis. Zinc deficiency was significantly associated with primary hypertension (hazard ratio [HR] 1.20, 95% confidence interval [CI] 1.14-1.25; P < .001), secondary hypertension (HR 1.82, 95% CI 1.45-2.29; P < .001), hypertension-related cardiac and renal complications (HR 1.69, 95% CI 1.49-1.92; P < .001), and hypertensive crisis (HR 1.09, 95% CI 1.01-1.18; P = .028). Dose-response analyses revealed a J-shaped association for primary hypertension, with elevated hazards at both low and high zinc concentrations. The association between zinc deficiency and primary hypertension was significantly stronger in men than in women (HR 1.28 vs 1.13; P for interaction = .021). Zinc deficiency was associated with incident hypertension and related complications, particularly secondary hypertension. Further prospective studies are warranted to determine whether correction of zinc deficiency modifies hypertension risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.